Technology
HPPT is a unique delivery system using live genetically modified Helicobacter pylori bacteria that carry new genes for specific therapeutic purposes.
Foreign Genes Vaccine antigens including whole proteins or specific epitopes can be expressed in HPPT so that their presence will trigger an effective immune response in the host.The added genes incorporated into HPPT could also code for pharmaceutical agents such as simple drugs, hormones or biologicals.
Ondek anticipates that this technology can succeed in treating diseases where other methods have failed.
Ondek will partner with leading pharmaceutical companies to use HPPT to deliver a range of proprietary products.
The HPPT has unique characteristics that make it ideal as a delivery system:
- it can be delivered orally (avoiding costs & risks associated with needles);
- it can deliver drugs over long periods of time with a single dose (similar to an infusion but without the risks or discomfort);
- it can deliver multiple vaccines or other substances concurrently (removing the need for multiple doses or vaccine boosters); and
- it is a simple and effective method for delivering bioactive substances to target tissues in controlled doses.
To date, Ondek is at the preclinical stage having achieved proof of concept in rodent models using urease as a carrier.
Ondek is currently building a family of patents around the HPPT and currently has two provisional patent applications in the US, Australia, Europe and other major markets.